Search the Newsreel

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Invest In Growth?

Cognition Therapeutics (NASDAQ:CGTX) is an early-stage company operating with a cash burn of US$20 million annually, with a cash runway of about 18 months based on its US$31 million cash reserves as of March 2026. While the company has reduced its cash burn by …

Pzena Investment Management (NASDAQ: CTSH) discloses 5.7% Cognizant ownership

Pzena Investment Management, LLC has disclosed a beneficial ownership of 5.7% in Cognizant Technology Solutions Corp, amounting to 26,844,745 shares. This stake, held on behalf of Pzena's clients, grants sole voting power over 20,970,336 shares and sole dispositive power over all 26,844,745 shares. The …

Cognex (CGNX) Stock Looks Overvalued On Cash Flow And Earnings

Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Organon (NYSE: OGN) announced it will release its second-quarter 2026 financial results through its Form 10-Q filing with the SEC, along with a Form 8-K disclosing non-GAAP financial measures. Due to its pending acquisition by Sun Pharmaceutical Industries Limited, the company has suspended quarterly …

Alpha Cognition (ACOG) Proxy Filing Summary

Alpha Cognition (ACOG) has scheduled its Annual General Meeting for June 19, 2025, where shareholders will vote on financial statements, director elections, auditor appointments, and a new stock and incentive plan. The board comprises six directors, a majority of whom are independent, with established …

Cognex Corporation announces Q2 2026 earnings release date

Cognex Corporation, a leader in industrial machine vision, will announce its second-quarter 2026 financial results on August 5, 2026, after market close. The company will host a conference call on August 6, 2026, at 8:30 a.m. ET to discuss these results. Investors can access …

Cognex Announces Second Quarter 2026 Earnings Release and Conference Call Dates

Cognex Corporation announced that it will release its second-quarter 2026 earnings on Wednesday, August 5, 2026, after market close. The company will also host a conference call on Thursday, August 6, 2026, at 8:30 a.m. Eastern Time to discuss the results, with details available …

Cognex Sets Aug. 6 Call to Discuss Second-Quarter Results

Cognex (NASDAQ: CGNX) will release its second-quarter 2026 earnings on Wednesday, August 5, 2026, after market close. The company will host a conference call on Thursday, August 6, 2026, at 8:30 a.m. Eastern Time to discuss the results. Investors can access the live webcast …

Organon Suspends Earnings Calls While Sun Pharma Deal Is Pending

Samsung Bioepis and Organon Broaden Biosimilar Access in Australia

Samsung Bioepis and Organon have expanded their collaboration in Australia to include an additional biosimilar, deepening their existing partnership. This agreement grants Organon exclusive commercial rights for the new biosimilar in Australia, while Samsung Bioepis retains development, manufacturing, and regulatory responsibilities. The expansion aims …

Invesco discloses 28,129,017 Cognizant Technology Solutions (CTSH) shares

Invesco Ltd., a Bermuda-based investment firm, has reported beneficial ownership of 28,129,017 shares of Cognizant Technology Solutions Corp. (CTSH) common stock, which represents 5.9% of the class as of March 31, 2026. The filing indicates that Invesco has sole voting power over 27,766,517 shares …

Sera Prognostics Q1 2026 Earnings: EPS Matches Estimates, No Revenue, Stock Jumps 9% - Forward Guidance Trends

Cognyte secures $5M contract

Cognyte has successfully secured a $5 million contract. This appears to be a significant win for the company, indicating new business or continued partnership.

Sera Prognostics Among 3 Intriguing Penny Stocks To Consider

Cognex resists instruments selloff with 19-week Trend Signal still intact

CGNX added 0.7% in a week when Technology and its instruments peer group both fell more than 4%, but the stock’s 60.5% Fair Value premium and only modest volume confirmation keep the next test important.

Cognizant lines up July 29 results call before market open

REG - Cambridge Cognition - Result of Retail Offer

Previsão COGN3 — Preço Alvo para 2027

SERA Forecast — Price Target — Prediction for 2027

Sera Prognostics Inc. (SERA) Q1 2026 Earnings: In-line EPS Report with Minimal Revenue and Stock Decline - Dividend Growth Analysis

Sera Prognostics Q1 2026 Earnings: In-Line Loss as Pre-Revenue Firm Advances Preterm Birth Test Commercialization - Short-Term Outlook

All You Need to Know About Sera Prognostics (SERA) Rating Upgrade to Buy

Why Is Cognizant (CTSH) Up 1.8% Since Last Earnings Report?

Cognizant launches $500 million share buyback program

Cognizant Technology Solutions Corporation (NASDAQ:CTSH) Looks Interesting, And It's About To Pay A Dividend

Sera Prognostics reports Q1 2026: revenue $14k, net loss $8.4M, cash ~$86.8M

Cogna (COGN3) tem lucro líquido de R$ 141,4 mi no 1º tri, com alta anual de 48,7%

Cognizant (Nasdaq: CTSH) posts Q1 2026 growth and unveils Project Leap cost program

Cognizant (CTSH) Q1 2026 Earnings Transcript

Sera Prognostics reports Q4 2025: $10k revenue, $7.9M Q4 net loss, $95.8M year-end cash

SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

Cogna (COGN3) tem lucro líquido de R$ 220 milhões no 4º tri, alta anual de 84,9%

Cambridge Cognition shares jump on India deal news

Cognizant Reports Fourth Quarter and Full-Year 2025 Results

Investors Continue Waiting On Sidelines For Cambridge Cognition Holdings Plc (LON:COG)

William Blair eleva classificação das ações da Cognizant para Outperform devido ao crescimento com IA - Investing.com Brasil